SRS Investment Management’s 10x Genomics TXG Stock Holding History

SRS Investment Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-504,257	Closed	-$9.81M	–	25
2024 Q2	$9.81M	Buy	+504,257	New	+$13.2M	0.13%	19
2024 Q1	–	Sell	-683,893	Closed	-$38.3M	–	27
2023 Q4	$38.3M	Sell	683,893 -365,317	-35%	-$15.9M	0.46%	15
2023 Q3	$43.3M	Sell	1,049,210 -1,124,903	-52%	-$58.5M	0.62%	14
2023 Q2	$121M	Sell	2,174,113 -831,314	-28%	-$45M	1.39%	12
2023 Q1	$168M	Hold	3,005,427	–	–	2.41%	7
2022 Q4	$110M	Hold	3,005,427	–	–	1.98%	7
2022 Q3	$85.6M	Buy	3,005,427 +247,182	+9%	+$9.42M	1.68%	9
2022 Q2	$125M	Buy	2,758,245 +2,548,380	+1,214%	+$132M	2.45%	8
2022 Q1	$16M	Hold	209,865	–	–	0.18%	26
2021 Q4	$31.3M	Buy	209,865 +169,414	+419%	+$25.9M	0.37%	19
2021 Q3	$5.89M	Buy	+40,451	New	+$6.94M	0.08%	23

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

SRS Investment Management's TXG Position: Q3 2024 in Review

SRS Investment Management sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 504,257 shares — an estimated $9.81M sold.

SRS Investment Management first reported a position in TXG in Q3 2021 and held it in 11 quarters. The position peaked at $168M in Q1 2023. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

SRS Investment Management reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
SRS Investment Management sold 504,257 10x Genomics shares in Q3 2024, an estimated $9.81M.
SRS Investment Management first reported a position in 10x Genomics in Q3 2021 and held it in 11 quarters.
SRS Investment Management's 10x Genomics position peaked at $168M in Q1 2023.
266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on SRS Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.